Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 10,529 matching trials from the live ClinicalTrials.gov search.
Conditions
Syncope, Pediatric, Congenital Athymia, Congenital Heart Disease, Arrhythmia, Arrhythmia in Children
Interventions
Zio monitor
Device
Lead sponsor
iRhythm Technologies, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boise, Idaho • Boston, Massachusetts + 1 more
Conditions
Opioid Use Disorder, Neonatal Abstinence Syndrome
Interventions
An implementation model for co-located Medications for Opioid Use Disorder (MOUD) prescription in the NICU
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite, Laxity; Skin
Interventions
collagenase clostridium histolyticum
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Coral Gables, Florida • Metairie, Louisiana • New York, New York
Completed Phase 2 Interventional Results available

Study of Apremilast in Atopic or Contact Dermatitis

NCT00931242
Conditions
Atopic Dermatitis, Allergic Contact Dermatitis
Interventions
Apremilast
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Not listed Not applicable Interventional Accepts healthy volunteers

Injectable Poly-L-Lactic Acid for Volumization and Adipogenesis of the Hip Dell

NCT05269654
Conditions
Skin Laxity
Interventions
injectable poly-L-lactic acid, Normal Saline
Device · Other
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
30 Years to 60 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Diego, California
Conditions
Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
Interventions
Not listed
Lead sponsor
Lexeo Therapeutics
Industry
Eligibility
18 Years to 67 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Cystic Fibrosis
Interventions
Yoga treatment program
Other
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
9 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
Chart Review, Survey
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Cytomegalovirus Infection
Interventions
Valganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Atlanta, Georgia • Rochester, Minnesota + 3 more
Conditions
Neimann-Pick Disease
Interventions
Vorinostat
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Lymphoproliferative Disorders, Lymphoma
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Tourettes Syndrome, Tic
Interventions
N-Acetylcysteine (NAC), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
8 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Prader-Willi Syndrome
Interventions
DCCR, Placebo for DCCR
Drug
Lead sponsor
Soleno Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
20
States / cities
Orange, California • Palo Alto, California • San Diego, California + 17 more
Active, not recruiting No phase listed Observational

Defining Endpoints in Becker Muscular Dystrophy

NCT05257473
Conditions
Becker Muscular Dystrophy, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Becker
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
6 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Orange, California • Aurora, Colorado • Iowa City, Iowa + 6 more
Conditions
Congenital Heart Disease, Fontan
Interventions
inhaled nitric oxide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
4 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
San Francisco, California
Conditions
Craniosynostosis, Sagittal
Interventions
Endoscopic strip craniectomy (with lateral osteotomies) with post-operative helmet therapy, Endoscopic strip craniectomy (without lateral osteotomies) with post-operative helmet therapy
Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 6 Months
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Neurodevelopmental Outcomes in Craniosynostosis Repair

NCT04072783
Conditions
Craniosynostoses
Interventions
MRI,DTI, functional MRI
Diagnostic Test
Lead sponsor
University of Arkansas
Other
Eligibility
Up to 4 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Little Rock, Arkansas
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Neural Correlates of Sensory Phenomena in Tourette Syndrome

NCT03914664
Conditions
Tourette Syndrome, Sensory Disorders, Hypersensitivity, Tics
Interventions
Electroencephalogram (EEG) testing procedure, Autonomic function testing procedure
Diagnostic Test
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Gout
Interventions
Placebo, RDEA3170 5 mg, RDEA3170 10 mg, RDEA3170 12.5 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
49
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 45 more
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Cystic Fibrosis
Interventions
KB001-A, Placebo Comparator
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
58
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more
Conditions
Severe Thalassemia
Interventions
Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Year to 16 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
18
States / cities
Los Angeles, California • Oakland, California • Washington D.C., District of Columbia + 15 more
Conditions
Becker Muscular Dystrophy
Interventions
(-)-epicatechin
Drug
Lead sponsor
Craig McDonald, MD
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Sacramento, California
Terminated Not applicable Interventional Results available

Polycystic Liver Disease in Kidney Transplant

NCT00934791
Conditions
Polycystic Liver Disease
Interventions
Tacrolimus, Sirolimus, Mycophenolate Mofetil, Prednisone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota